TrumpRx Prescription Drug Site Labelled 'Not a Solution' for Most Patients
The Trump administration has launched TrumpRx, a new website aimed at reducing prescription drug prices, but health experts warn it offers only a limited selection of medications and may not provide genuine savings for many Americans. At a press conference last week, President Trump hailed the initiative as "the largest reduction in prescription drug prices in history," yet the site lists just 43 drugs, with more than half available as cheaper generics elsewhere.
Limited Offerings and Higher Costs
Sean Sullivan, a professor of health economics and policy at the University of Washington, stated that TrumpRx is "not a solution for high drug prices in the United States." He explained that consumers can often find better deals through insurance, local pharmacies, or services like Cost Plus Drugs. For instance, the medication Protonix, used for gastrointestinal issues, is priced at $200.10 on TrumpRx, while its generic version costs $6.07 on Cost Plus Drugs. Similarly, Xeljanz, for rheumatoid arthritis, is listed at $1,518 on TrumpRx, but GoodRx notes it is typically free with most insurance plans.
Rena Conti, an associate professor at Boston University, added that the site "has added to the complexity" of America's already complicated healthcare system, rather than simplifying it. She advised patients to consult their local pharmacists for the best deals instead.
Broader Healthcare Context and Criticisms
In the US, drug prices are 2.7 times higher than in comparable countries, according to a 2022 report from the Department of Health and Human Services. A KFF survey found that 80% of adults deem prescription drug costs "unreasonable," and 30% have skipped medications due to expense. Meanwhile, Republicans in Congress have proposed nearly $1 billion in Medicaid cuts and allowed Affordable Care Act tax credits to expire, potentially increasing healthcare costs further.
TrumpRx, reportedly powered by GoodRx, struggles to compete with established sites like Cost Plus Drugs, which offers over 2,000 medications. Sarah Karlin-Smith of Public Citizen criticised the administration's portrayal, saying it "bears no relation to reality" and could lead some Americans to overspend on drugs.
Niche Benefits and Underlying Issues
While TrumpRx may benefit niche groups, such as those seeking fertility or weight loss drugs not covered by insurance, its impact is limited. For example, Gonal F, a fertility drug, costs $168 on TrumpRx versus $432 on Alto Pharmacy. However, Sean Tipton of the American Society for Reproductive Medicine noted that drug costs are only a small part of IVF expenses, questioning the program's overall helpfulness.
Weight loss drugs like Wegovy and Ozempic are listed, but Conti pointed out that discounts for these expire soon and apply only to low doses. She also raised concerns about missing drugs, asking, "where are the other drug companies and where are the other drugs?" given that 17 manufacturers have signed deals.
Sullivan concluded that TrumpRx distracts from needed policy reforms, stating, "It just obfuscates what we really need to be doing... thoughtful, careful policy approaches to managing drug costs."
